Core Viewpoint - CytoMed Therapeutics Limited addresses and rejects recent misleading claims regarding its research programs, clinical progress, and operations, emphasizing its commitment to transparency and accurate communication [1][2][5]. Company Overview - CytoMed is a clinical stage biopharmaceutical company based in Singapore, focused on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][7]. - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [7]. Research and Development - The company's research primarily focuses on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, grounded in established immunological science [3]. - CytoMed's lead CAR γδ T cell program has received regulatory approval for a first-in-human clinical trial, which is currently ongoing at the National University Hospital in Singapore [3]. - Other therapeutic candidates, including iPSC-derived γδ NKT cell candidates, are still in preclinical development [4]. Regulatory and Operational Compliance - CytoMed asserts that it operates in compliance with applicable regulations and follows appropriate development practices for its current stage [5]. - The company emphasizes that any claims regarding its regulatory status, manufacturing capabilities, governance, or financial transparency that contradict its statements are inaccurate or taken out of context [5]. Commitment to Transparency - CytoMed is dedicated to advancing its pipeline responsibly and ensuring timely communication of accurate information through official disclosures [6]. - The company reserves the right to take action against the dissemination of false or misleading information that could harm its reputation or stakeholders [6].

Core Viewpoint - CytoMed Therapeutics Limited is advancing its clinical-stage biopharmaceutical initiatives, focusing on donor-derived cell-based immunotherapies for various cancers, while also diversifying its product pipeline through the development of Natural Killer cells [1][2]. Group 1: Company Developments - CytoMed is establishing a new subsidiary, LongevityBank, to enhance access to cord blood for cell-based therapies [1]. - The company has sufficient resources to fund its activities for at least a year due to its low-cost infrastructure in Southeast Asia [2]. - CytoMed has entered a Memorandum of Understanding with Universiti Malaya to conduct a Phase I clinical trial for its allogeneic unmodified Gamma Delta T cells targeting no-option cancer patients in Malaysia [3]. Group 2: Clinical Trials and Research - The ongoing clinical trials include a Phase I trial for chimeric antigen receptor T (CAR T) cells at National University Hospital Singapore, targeting various cancer types [3]. - CytoMed's unmodified gamma delta T cells have shown potential in international clinical trials to kill cancer cells, including brain cancers [4]. - A recent preclinical study co-authored by CytoMed suggests the potential of its allogeneic gamma delta T cell therapy for treating acute myeloid leukemia [4]. Group 3: Strategic Partnerships and Future Plans - The company is exploring long-term strategic partnerships with biotechs and hospitals to strengthen its business and international presence [2]. - CytoMed's Chairman intends to increase his shareholding in the company, indicating confidence in its future [2]. - The company plans to seek shareholder feedback on a scheme allowing access to its donor-derived gamma delta T cells, subject to medical approval [5].

Core Viewpoint - CytoMed Therapeutics Limited has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre to conduct a first-in-human Phase I clinical trial for its allogeneic unmodified Gamma Delta T cells, targeting no-option cancer patients in Malaysia [1][5] Group 1: Clinical Trials and Collaborations - The new trial will complement CytoMed's ongoing Phase I CAR T clinical trial at National University Hospital Singapore, which utilizes engineered γδ T cells to target various cancers [2] - CytoMed's Chairman highlighted that the collaboration aims to provide affordable immunotherapy options for patients with limited alternatives, leveraging the innate ability of γδ T cells to detect and kill cancer cells [3] - The company has previously collaborated with MD Anderson Cancer Center, resulting in a publication that supports the potential of its CTM-GDT for treating acute myeloid leukemia [3][4] Group 2: Technology and Innovation - CytoMed focuses on developing allogeneic immunotherapies using γδ T cells derived from healthy donors, which are more cost-effective and logistically simpler compared to autologous therapies [3] - The company was established in 2018, spun off from Singapore's Agency for Science, Technology and Research, and aims to create novel cell-based therapies inspired by the success of existing CAR-T therapies [6]

Core Viewpoint - CytoMed Therapeutics Limited has successfully completed the acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited, enhancing its capabilities in developing affordable cell-based immunotherapies for cancer treatment [1][2] Group 1: Acquisition Details - The acquisition of TCB-002 complements CytoMed's strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform for treating cancer and autoimmune diseases [2] - TCB-002 has completed a Phase I clinical trial in Europe and received orphan drug designation from the U.S. FDA for treating Acute Myeloid Leukemia [2] Group 2: Strategic Collaborations - CytoMed is in advanced discussions with potential partners to enhance and repurpose TCB-002 for cancer treatment applications in China and India, focusing on a new manufacturing method that does not require living cells [3] - This non-cell-based approach allows for easier scaling within China due to strict regulations on biological materials, providing advantages in treatment speed, accessibility, and cost-effectiveness compared to autologous therapies [3] Group 3: Regulatory Environment - The new initiative to establish a presence in China replaces previous agreements with Chinese parties and aligns with new regulations from the State Council aimed at liberalizing the clinical use of cellular products [4] - State Council Decree No. 818 establishes a regulatory pathway for cell therapies in China, allowing for a streamlined process from clinical research to clinical application, which is beneficial for CytoMed's allogeneic gamma delta T cell platform [5] Group 4: Current Developments - CytoMed's gamma delta T cell technology has been granted a patent by the China National Intellectual Property Administration, and the company is conducting a Phase I clinical trial in Singapore [6] - The completion of the acquisition is not expected to have an immediate material financial impact on the company [7] Group 5: Company Background - CytoMed, incorporated in 2018, focuses on developing novel cell-based allogeneic immunotherapies for various cancers, inspired by the success of CAR-T therapies [8]

Core Insights - CytoMed Therapeutics Limited has secured a non-dilutive investment of up to US$500,000 from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies [3][4] - The strategic vision for LongevityBank is to leverage personalized cellular banking services while CytoMed concentrates on donor-derived allogeneic therapies, which are currently undergoing clinical trials in Singapore and India [2][5] - ICH Capital's investment reflects a belief in the future of healthcare through cell banking and autologous therapies, with plans to explore joint ventures in cancer care centers in Southeast Asia [4] Company Developments - CytoMed is conducting an IND Phase I clinical trial for its allogeneic gamma delta T cell platform in Singapore, with a focus on expanding into the Chinese market following new regulatory pathways for cell therapies [5][7] - The company is in discussions with Chinese firms to develop cost-effective methods for manufacturing donor-derived allogeneic gamma delta T cells [6] - CytoMed's proprietary technologies, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, are aimed at creating novel immunotherapies for various cancers [8][9]

Core Insights - CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][3] - Executive Chairman Peter Choo has increased his shareholding in the company, now owning 21.95% of total outstanding shares, indicating his confidence in the company's potential [1][2] Company Overview - CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [3] - The company specializes in proprietary technologies, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, aimed at creating novel allogeneic immunotherapies for cancer treatment [3] Market Context - There is rising investor interest in biotherapeutics in Asia, particularly in China, which presents unique opportunities for innovation and cost-competitive patient access [2] - The expanding healthcare and medical travel ecosystem in Southeast Asia, along with increasing healthcare costs in the West, further enhances the market potential for CytoMed's offerings [2]

Core Viewpoint - CytoMed Therapeutics Limited has submitted a cash bid for the acquisition of potentially synergistic assets from TC BioPharm Limited, aiming to enhance its expertise in allogeneic cell therapies for cancer treatment [1][3]. Group 1: Company Overview - CytoMed is a clinical stage biopharmaceutical company based in Singapore, focused on developing donor-derived cell-based immunotherapies for various cancers [1][6]. - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [6]. Group 2: Proposed Acquisition - The proposed acquisition is intended to strengthen CytoMed's capabilities in using allogeneic cell therapies, accelerating its commercialization timeline and providing affordable treatment options for patients with unmet needs [3][4]. - This acquisition represents CytoMed's second acquisition in approximately one year, following the acquisition of a licensed cord blood bank in Malaysia [4]. Group 3: Clinical Development - Both CytoMed and TC BioPharm are engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment, with TC BioPharm having completed a Phase I clinical trial and CytoMed conducting its Phase I ANGELICA Trial [2]. - CytoMed aims to leverage Southeast Asia's low-cost infrastructure to make cell therapies more accessible [4]. Group 4: Strategic Insights - The Chairman of CytoMed highlighted the potential of donor-derived gamma delta T cells for cancer treatment, referencing a recent publication from MD Anderson Cancer Center that supports this approach [4]. - The company is focused on developing cost-effective manufacturing processes for its therapies, particularly in light of recent developments in China to boost cell therapies [4].

Core Insights - The company reported a 100% increase in revenue to SGD 156,000 for the six months ended June 30, 2025 [2] - A net loss of $2.05 million was recorded, which could be reduced to $1.44 million when excluding certain costs [2] - Cash and bank balances stood at $2.86 million as of June 30, 2025, with a net tangible asset (NTA) of $7.15 million [2] Financial Performance Overview - Revenue for the first half of 2025 was generated from private banking services after acquiring the necessary license and assets [3] - Other operating income decreased by 8.5% year-on-year [2] - Loss per share was reported at $0.19 for the six months ended June 30, 2025 [2]

Financial Performance - Revenue increased by 100% to $156,000 for the six months ended June 30, 2025, compared to the same period in 2024 [3] - Other operating income decreased by 8.5% year on year, from $422,000 in H1 2024 to $386,000 in H1 2025 [5] - Net loss reported was $2,050,000 in 2025, which could be reduced to $1,440,000 when excluding certain costs [3][7] - Loss per share was $0.19 for the six months ended June 30, 2025 [4] - Cash and bank balances decreased from $4,970,000 as of December 31, 2024, to $2,860,000 as of June 30, 2025 [7] Business Line Performance - Revenue of $156,000 was generated from private banking services after acquiring a license and certain assets under IPSE depository in Malaysia [4] - Research expenses increased by 19.3% from $974,000 in H1 2024 to $1,160,000 in H1 2025, driven by higher employee benefits and clinical trial expenses [6] Market Data - The company reported a net loss in currency exchange of $402,000 and a net loss of $227,000 in fair value changes on warrant liability [5] - As of June 30, 2025, there were 72,371 warrants outstanding, with fair value changes of $76,000 recorded in the profit and loss account [8] Company Strategy and Industry Competition - The company is focusing on clinical trials and collaborations, with ongoing projects including CTM and iPSC GDNKT [9][10] - A new ATM agreement was signed with Levity to raise up to $4.3 million, indicating a strategy to enhance funding [11] - The corporate banking business is being rebranded as Longevity Bank, reflecting a strategic shift [11] Management Commentary on Operating Environment and Future Outlook - Management highlighted the completion of dose level one in a clinical trial and plans to complete Phase one trials in 2026 [9] - The company aims to apply for GDT trials in Malaysia and other locations, indicating a focus on expanding its market presence [10] Other Important Information - The company’s manufacturing facility has been audited by the Ministry of Health of Malaysia, ensuring compliance and operational readiness [11] Q&A Session Summary - The earnings call concluded without any questions from participants, indicating a lack of immediate inquiries regarding the financial performance or strategic direction [12]

Core Insights - CytoMed Therapeutics Limited has published a preclinical study indicating the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML) [1][2] - The study was conducted in collaboration with The University of Texas, MD Anderson Cancer Center, under a research agreement established in May 2023 [1] - The findings support further clinical studies of allogeneic donor-derived γδ T cells for AML and other cancers, with plans to advance their next γδ T cell-based product into clinical trials [2] Company Overview - CytoMed, incorporated in 2018, is a clinical stage biopharmaceutical company focused on developing novel donor-derived cell-based immunotherapies for various cancers [3] - The company utilizes proprietary technologies, including gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, inspired by the success of CAR-T therapies in hematological malignancies [3] - CytoMed aims to provide innovative immunotherapy options for patients with limited treatment alternatives, particularly in Southeast Asia [3]